Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Brigham and Women's Hospital
M.D. Anderson Cancer Center
Stanford University
M.D. Anderson Cancer Center
Eli Lilly and Company
Taichung Veterans General Hospital
Bayer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
National Taiwan University Hospital
National Taiwan University Hospital
University of Chicago
Gustave Roussy, Cancer Campus, Grand Paris
Erasca, Inc.
South Egypt Cancer Institute
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
The Cleveland Clinic
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Second Affiliated Hospital of Nanchang University
National Cancer Institute (NCI)
University Health Network, Toronto
University Health Network, Toronto
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Exelixis
Institut du Cancer de Montpellier - Val d'Aurelle
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Eli Lilly and Company
Exelixis
Sensei Biotherapeutics, Inc.
Imperial College London
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center
Instituto do Cancer do Estado de São Paulo
Eli Lilly and Company